{"aliases":[{"type":"USBrandName","name":"Zejula"},{"type":"ChemicalStructureName","name":"2H-indazole-7-carboxamide, 2-(4-(3S)-3-piperidinylphenyl)-, 4-methylbenzenesulfonate, hydrate (1:1:1)"},{"type":"CASRegistryName","name":"1613220-15-7"}],"definition":{"html":"An orally bioavailable, hydrated, tosylate salt form of niraparib, an inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.","text":"An orally bioavailable, hydrated, tosylate salt form of niraparib, an inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/niraparibtosylatemonohydrate","text":"Niraparib Tosylate Monohydrate"},"nciConceptId":"C133238","nciConceptName":"Niraparib Tosylate Monohydrate","termId":615263,"name":"niraparib tosylate monohydrate","firstLetter":"n","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"niraparib-tosylate-monohydrate"}